IP Library Granted Patent US 9,101,636
Granted Patent B2
US 9,101,636 · App. 14/091,817 · Granted Aug 11, 2015

Methods and compositions for self-regulated release of active pharmaceutical ingredient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,101,636
App. No.
14/091,817
Granted
Aug 11, 2015
Kind
B2
Abstract

An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Claims (10)

1. An abuse deterrent pharmaceutical composition comprising an immediate release unit dose of:

a. a pharmaceutically active ingredient;

b. an acid soluble ingredient comprising a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate; and

c. a buffering ingredient;

wherein the acid soluble ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when three unit doses or greater of the composition is ingested and wherein the buffering ingredient comprises one or more of calcium carbonate, sodium bicarbonate, magnesium oxide, tribasic sodium phosphate, or combinations thereof and is present in the amount of 45-95 wt % of the pharmaceutical composition.

2. The composition of claim 1 , wherein the pharmaceutically active ingredient comprises a drug susceptible to abuse.

3. The composition of claim 1 , wherein the pharmaceutically active ingredient comprises a drug with narrow therapeutic index.

4. The composition of claim 1 , wherein the acid soluble ingredient comprises calcium carbonate, cationic copolymer, or combinations thereof.

5. The composition of claim 1 , wherein the pharmaceutically active ingredient is contained within a matrix of the acid soluble ingredient.

6. The composition of claim 1 , wherein the acid soluble ingredient is present in an amount of about 1 wt % to about 40 wt % of the pharmaceutical composition.

Assignments (5)
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2014
From: BRZECZKO, ALBERT W.; HOLLENBECK, R. GARY
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 032223/0481 →